Hunter C. Smith serves as the Chief Financial Officer at Rhythm Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity. With a robust background in finance and healthcare, Smith has been instrumental in steering the company's financial strategy and growth. Prior to joining Rhythm Pharmaceuticals, he held several senior financial positions, including CFO roles at companies such as Bioverativ Inc. and Human Genome Sciences, where he honed his expertise in financial planning and strategic development within the biotech industry. At Rhythm Pharmaceuticals, Smith's role encompasses overseeing the company's financial operations, including budgeting, forecasting, and investor relations. His strategic vision has been crucial in navigating the company through the complex landscape of drug development and commercialization. Under his leadership, Rhythm Pharmaceuticals successfully launched IMCIVREE, a first-in-class therapy for obesity caused by genetic deficiencies, marking a significant milestone in the company's journey. Smith's ability to secure funding and manage resources efficiently has been pivotal in advancing the company's pipeline and expanding its reach to patients in need. Smith's achievements extend beyond his current role, as he has been recognized for his contributions to the biotech sector. He holds a Bachelor of Science in Business Administration from the University of North Carolina at Chapel Hill and an MBA from the Darden School of Business at the University of Virginia. His comprehensive understanding of financial intricacies combined with a deep commitment to improving patient outcomes has solidified his reputation as a respected leader in the biopharmaceutical industry.